These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12139751)

  • 1. A Tyr346-->Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy.
    Mumford AD; Laffan M; O'Donnell J; McVey JH; Johnson DJ; Manning RA; Kemball-Cook G
    Br J Haematol; 2002 Aug; 118(2):589-94. PubMed ID: 12139751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
    Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
    Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII.
    Wakabayashi H; Monaghan M; Fay PJ
    J Biol Chem; 2014 May; 289(20):14020-9. PubMed ID: 24692542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?
    Lyall H; Hill M; Westby J; Grimley C; Dolan G
    Haemophilia; 2008 Jan; 14(1):78-80. PubMed ID: 18034822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.
    Hakeos WH; Miao H; Sirachainan N; Kemball-Cook G; Saenko EL; Kaufman RJ; Pipe SW
    Thromb Haemost; 2002 Nov; 88(5):781-7. PubMed ID: 12428094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa.
    Wakabayashi H; Wintermute JM; Fay PJ
    Thromb Haemost; 2014 Jul; 112(1):43-52. PubMed ID: 24599523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.
    Pipe SW; Saenko EL; Eickhorst AN; Kemball-Cook G; Kaufman RJ
    Blood; 2001 Feb; 97(3):685-91. PubMed ID: 11157485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.
    Wakabayashi H; Fay PJ
    Biochemistry; 2013 Jun; 52(22):3921-9. PubMed ID: 23659383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.
    Venkateswarlu D
    BMC Struct Biol; 2010 Feb; 10():7. PubMed ID: 20184747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability.
    Wakabayashi H; Griffiths AE; Fay PJ
    J Biol Chem; 2011 Jul; 286(29):25748-55. PubMed ID: 21628455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.
    Bloem E; Meems H; van den Biggelaar M; Mertens K; Meijer AB
    J Biol Chem; 2013 Sep; 288(36):26105-26111. PubMed ID: 23884417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
    Gale AJ; Radtke KP; Cunningham MA; Chamberlain D; Pellequer JL; Griffin JH
    J Thromb Haemost; 2006 Jun; 4(6):1315-22. PubMed ID: 16706977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.
    Johnson DJ; Pemberton S; Acquila M; Mori PG; Tuddenham EG; O'Brien DP
    Thromb Haemost; 1994 Apr; 71(4):428-33. PubMed ID: 8052958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
    Khrenov AV; Ananyeva NM; Saenko EL
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.
    Parker ET; Lollar P
    Biochemistry; 2007 Aug; 46(34):9737-42. PubMed ID: 17676877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
    Takeyama M; Nogami K; Matsumoto T; Soeda T; Suzuki T; Hattori K; Shima M
    Thromb Haemost; 2010 Jan; 103(1):94-102. PubMed ID: 20062922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.
    O'Brien DP; Pattinson JK; Tuddenham EG
    Blood; 1990 Apr; 75(8):1664-72. PubMed ID: 2109644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
    J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.